Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating.Maximize Your Portfolio with Data Driven ...

AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Global healthcare private equity (PE) deal value surged to an estimated $115 billion in 2024, marking the second-highest ...

The Banks Public Private Partnership, a joint venture of the city of Cincinnati and Hamilton County, has issued a new call ...

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

Aeon Biopharma Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -92.52%. The profit margin, also known as the revenue ratio or gross profit ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 13.37%, which has investors questioning if this is right time to sell.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...